MedicineNews.net - Medical Updates

Fingolimod is the first and only disease-modifying therapy with proven superiority versus Glatiramer acetate in relapsing remitting multiple sclerosis

Full data of the ASSESS study, which has evaluated the efficacy of oral, once-daily Fingolimod ( Gilenya ) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of Glatiramer acetate 20mg in r ... read article

Relapsing multiple sclerosis: oral Ozanimod has shown improvements compared to Interferon beta-1a for the primary endpoint of annualized relapse rate

SUNBEAM trial, evaluating the efficacy and safety of O)zanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis ( RMS ), met the primar ... read article

Oral Ozanimod, compared to Interferon beta-1a, reduces annualized relapse rate in patients with relapsing multiple sclerosis

The phase III SUNBEAM trial, evaluating the efficacy and safety of Ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis ( RMS ), m ... read article

Concussion in teenagers increases the risk of multiple sclerosis in later life

Concussion in teenagers increases the risk of multiple sclerosis in later life. However, there is no association with multiple sclerosis for concussion in younger children. The results have demonstr ... read article

Multiple sclerosis: chemokine receptor CCR2, a key protein involved in a super-inflammatory immune response

Published in the journal Nature Communications, the researchers at the University of Adelaide have identified a key protein involved in a super-inflammatory immune response that drives the progression ... read article

Lemtrada, a new treatment option for patients with multiple sclerosis, recommended by NICE

The National Institute for Health and Care Excellence ( NICE ) has recommended the use of multiple sclerosis drug Alemtuzumab ( Lemtrada ). Alemtuzumab has been described by experts as a revolution ... read article

Fingolimod for treatment of relapsing forms of multiple sclerosis

Fingolimod ( Gilenya, FTY720 ) is an oral sphingosine-1-phosphate analogue that was approved by the FDA ( Food and Drug Administration ) in 2010 for the treatment of relapsing forms of multiple sclero ... read article

FDA has approved a new formulation of Copaxone, three-times-a-week

The FDA ( Food and Drug Administration ) has approved the supplemental new drug application ( sNDA ) for three-times-a-week Copaxone ( Glatiramer acetate ) 40mg/mL. This new formulation will allow for ... read article

Aubagio for the treatment of relapsing forms of multiple sclerosis: safety information

Teriflunomide ( Aubagio ) is an immunomodulatory drug inhibiting pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase. Teriflunomide inhibits rapidly dividing cells, includ ... read article

FDA: Aubagio a oral treatment for relapsing multiple sclerosis

Genzyme, a Sanofi company, has announced that the FDA ( Food and Drug Administration ) has approved Aubagio ( Teriflunomide ) as a new once-daily, oral treatment indicated for patients with relapsing ... read article

Interferon-beta for secondary progressive multiple sclerosis

Therapy with either recombinant beta-1a or beta-1b interferons ( IFNs ) is approved for relapsing remitting multiple sclerosis ( RRMS ). A major unanswered question is whether this treatment is able t ... read article

Sanofi and its subsidiary Genzyme have announced results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug Alemtuzumab ( Lemtrada ) to the approve ... read article

Ampyra improves walking in adults with multiple sclerosis, FDA approved

The FDA ( Food and Drug Administration ) has approved Ampyra ( Dalfampridine ) extended release tablets to improve walking in patients with multiple sclerosis. In clinical trials, patients treated wi ... read article

Oral Laquinimod for multiple sclerosis: initial results from ALLEGRO study

Teva Pharmaceutical and Active Biotech have announced initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis patients treated with 0. ... read article

Methylprednisolone added to Interferon beta-1a reduces relapse rate in patients with relapsing-remitting multiple sclerosis

Addition of oral Methylprednisolone to standard treatment of subcutaneous Interferon beta-1a substantially reduces the relapse rate in patients with relapsing-remitting multiple sclerosis. Like oth ... read article